In An Organic Compound Patents (Class 424/1.65)
  • Patent number: 11542267
    Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 3, 2023
    Assignees: Australian Nuclear Science and Technology Organisation, The Australian National University
    Inventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
  • Patent number: 11478558
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 25, 2022
    Assignee: The Johns Hopkins University
    Inventors: Sangeeta Ray, Martin G. Pomper
  • Patent number: 11452785
    Abstract: In general, the patent herein is a radioactive chemical which attaches to the virus and releases radiation which kills the virus. Specifically, the chemical is an alpha-ketoamide designed to attach to the virus. However, instead of 2 bromine atoms, Iodine-131 is at the location of where the bromine atoms would have been. Iodine-131 is a radioactive element which releases ionizing radiation. The virus with which this radioactive chemical is designed for is the COVID-19 coronavirus, although the patent is for any virus. Since, modifications can be made in chemical structure and radioactive chemical species, the patent is for any and all chemicals which contain any type of radioactive element to kill or disrupt any type of virus.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: September 27, 2022
    Inventor: Zachary Charles Crouch
  • Patent number: 11413360
    Abstract: The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 16, 2022
    Assignees: Technische Universität München, Technische Universität München—Klinikum Rechts der Isar
    Inventors: Alexander Josef Wurzer, Hans-Jürgen Wester, Matthias Johannes Eiber
  • Patent number: 11406723
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: August 9, 2022
    Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
  • Patent number: 11400057
    Abstract: The present invention relates to methods of treating female reproductive tract irritation (such as pain and pruritus) or/and inflammation.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: August 2, 2022
    Assignee: University of Rochester
    Inventors: David Foster, Megan L. Falsetta Wood, Richard P. Phipps
  • Patent number: 11384106
    Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F18) radioisotope, or other radionuclide.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: July 12, 2022
    Assignee: Emory University
    Inventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
  • Patent number: 11285244
    Abstract: The invention relates to a method for preparing a polymer scaffold that comprises the steps of providing a piece of a fabric of filaments of a first biodegradable or biocompatible polymer, applying a coating of a second polymer to said arrangement of filaments, and stretching the piece along its axis of longitudinal extension, thereby obtaining an aligned microfibrillar scaffold. The invention further relates to a method for providing an artificial tissue, and to a microfibrillar scaffold of aligned filaments obtained by the method of the invention.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 29, 2022
    Assignees: ETH ZÜRICH, UNIVERSITÄT ZÜRICH
    Inventors: Simon Philipp Hoerstrup, Seyedvahid Hosseini, Viola Vogel
  • Patent number: 11285223
    Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 29, 2022
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
  • Patent number: 11266739
    Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: March 8, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventor: Mark J. Gilbert
  • Patent number: 11167048
    Abstract: Disclosed are compositions and methods relating to prostate cancer. In particular, disclosed are bivalent targeting ligands that specifically bind prostate specific membrane antigen and gastrin-releasing peptide receptor. Bivalent binding agents disclosed herein can be used to image a tissue in a subject in need thereof and to diagnose prostate cancer in a subject in need thereof. Bivalent binding agents disclosed herein can be used to treat prostate cancer in a subject in need thereof.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 9, 2021
    Assignee: The Curators of the University of Missouri
    Inventors: Charles Jeffrey Smith, Rajendra Prasad Bandari
  • Patent number: 11111243
    Abstract: The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 7, 2021
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
  • Patent number: 11077110
    Abstract: Provided herein are compositions and methods for treating or preventing metabolic disorders. In particular, provided herein are compositions, methods, and uses of Cyclin-dependent Kinase 6 (CDK6) inhibitors for treating and preventing metabolic diseases (e.g., type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides).
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 3, 2021
    Assignee: Tufts Medical Center
    Inventor: Miaofen G. Hu
  • Patent number: 11071714
    Abstract: Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 27, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Shutao Guo
  • Patent number: 11065349
    Abstract: This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include 18F-labeled BODIPY compounds and derivative thereof. Also provided are tracer kits containing a sterile formulation of a BODIPY dye either in a radio-labeled or pre-labeled state, and methods for imaging heart perfusion using the 18F-labeled dual mode tracers.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 20, 2021
    Inventors: Peter S. Conti, Zibo Li, Shuanglong Liu, Dan Li
  • Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 11027029
    Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 8, 2021
    Assignee: Cellbion Co., Ltd
    Inventors: Jae Min Jeong, Sung-Hyun Moon, Yun-Sang Lee
  • Patent number: 11020493
    Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: June 1, 2021
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
  • Patent number: 10980901
    Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 20, 2021
    Assignees: The European Atomic Energy Community (EURATOM), Represented by the European Commission, Universität Heidelberg
    Inventors: Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Uwe Haberkorn, Frederik Giesel, Clemens Kratochwil
  • Patent number: 10968245
    Abstract: The invention provides a method for preparing a technetium-99m tricarbonyl intermediate. The method comprises reacting a manganese carbonyl compound used as a carbon monoxide source with pertechnetate and water to obtain the technetium-99m tricarbonyl intermediate. The method for preparing a technetium-99m tricarbonyl intermediate in an embodiment of the invention can complete the preparation of the intermediate at atmospheric pressure and room temperature. The method is easy to operate, uses easily obtained raw materials, has a high labeling yield, and can be used to prepare various types of technetium tricarbonyl labeled probes.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: April 6, 2021
    Assignee: Institute of High Energy Physics, Chinese Academy of Sciences
    Inventors: Wenjiang Yang, Yu Liu, Jingquan Xue, Yanhua Zhang
  • Patent number: 10910123
    Abstract: Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 2, 2021
    Assignee: Lantheus Medical Imaging, Inc.
    Inventor: Keith R. Olewine
  • Patent number: 10898594
    Abstract: PAMAM dendrimer based CEST imaging agents, pharmaceutical compositions comprising the same and methods of uses thereof are disclosed.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: January 26, 2021
    Assignee: The Johns Hopkins University
    Inventors: Wojciech Lesniak, Sridhar Nimmagadda, Nikita Oskolkov, Michael McMahon, Xiaolei Song, Martin G. Pomper
  • Patent number: 10870629
    Abstract: The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 22, 2020
    Assignee: FUTURECHEM CO., LTD.
    Inventors: Dae Yoon Chi, Byoung Se Lee, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Min Hwan Kim, Mi Hyun Kim, Kyo Chul Lee, Yong Jin Lee, Ji Ae Park, Ran Ji Yoo, Sang Moo Lim
  • Patent number: 10835624
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Vincent Darmency, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden, Emanuele Gabellieri
  • Patent number: 10802094
    Abstract: Systems and methods for magnetic resonance imaging (“MRI”) of multiple different nuclear spin species using the same radio frequency (“RF”) coil are described. Generally, multiple different nuclear spin species are imaged using the same RF coil by using an MRI system whose magnetic field can be rapidly ramped between a number of different, and arbitrary, magnetic field strengths. The magnetic field of this MRI system can be ramped to different values in reasonable amounts of time (e.g., in a time frame that is feasible within an imaging study).
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 13, 2020
    Assignee: SYNAPTIVE MEDICAL (BARBADOS) INC.
    Inventor: Jeff A. Stainsby
  • Patent number: 10765748
    Abstract: In various aspects, embodiments of the present invention are directed to a series of multivalent dendrons containing a bioactive peptide domain and surface-binding catechol domains. In some embodiments, these multivalent dendrons were obtained through solid phase synthesis and have a strong binding affinity to metal oxide surfaces such as, TiO2, ZrO2, CeO2, and Fe3O4, SiO2, as well as other inorganic surfaces such as hydroxyapatite, silver, fluorapatite, calcium carbonate and gold. These catechol-bearing dendrons provide a fast and efficient method to functionalize a wide range of inorganic materials with bioactive peptides and have the potential to be used in coating orthopaedic implants and fixation devices.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: September 8, 2020
    Assignee: University of Akron
    Inventors: Matthew Becker, Wen Tang
  • Patent number: 10758635
    Abstract: The present invention relates to 99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well methods of preparing such compositions from the kit. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 1, 2020
    Assignee: Serac Healthcare Limited
    Inventor: David Jonathan Barnett
  • Patent number: 10744211
    Abstract: The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 18, 2020
    Assignee: University of Massachusetts
    Inventors: Guozheng Liu, Shuping Dou
  • Patent number: 10744214
    Abstract: The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: August 18, 2020
    Assignee: STC.UNM
    Inventor: Jeffrey P. Norenberg
  • Patent number: 10717946
    Abstract: Methods for adjusting the solubility of a botanical oil in water, along with the resulting modified botanical oil and related products (e.g., treatment compositions, wipes, absorbent articles, etc.) are provided. In one embodiment, the method includes reacting the botanical oil to form a reactive product (e.g., having a hydroxyl group); and attaching a hydrophilic end group (e.g., a carboxylic acid, a carboxylic acid salt, a sugar, etc.) on the reactive product to form a modified botanical oil. The modified botanical oil generally, in most embodiments, has a greater solubility in water than the botanical oil (e.g., a solubility in water of about 10 grams per 100 grams of water or greater, such as completely soluble in water). The botanical oil includes, in one particular embodiment, an essential oil, such as those essential oil that include at least one terpene compound.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: July 21, 2020
    Assignee: Kimberly-Clark Worldside, Inc.
    Inventors: David William Koenig, Mary Kay Foegen, Corey Thomas Cunningham, Aimin He, Yang Huang
  • Patent number: 10688200
    Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: June 23, 2020
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
  • Patent number: 10660976
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 26, 2020
    Assignee: Washington University
    Inventor: Vijay Sharma
  • Patent number: 10646598
    Abstract: Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: May 12, 2020
    Assignee: University of Southern California
    Inventors: Peter S. Conti, Hancheng Cai, Zibo Li, Shuanglong Liu
  • Patent number: 10633404
    Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F18) radioisotope, or other radionuclide.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 28, 2020
    Assignee: Emory University
    Inventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
  • Patent number: 10561379
    Abstract: The present invention concerns a positron emission tomography (PET) contrast agent or imaging tracer comprising a red blood cell (RBC) internally labeled with 2-deoxy-2-(18F)fluoro-D-glucose (FDG); a method of preparing RBCs of a human or non-human animal for PET, comprising labeling RBCs in vitro with FDG to produce FDG-labeled RBCs; a method for in vivo imaging of RBCs using PET, comprising: introducing RBCs internally labeled with FDG (FDG-RBCs) into the circulatory system of a human or non-human animal subject in vivo; and PET imaging the introduced FDG-RBCs in the subject; a composition useful for labeling RBCs, and a kit for labeling RBCs.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: February 18, 2020
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventor: Jung Wook Choi
  • Patent number: 10537651
    Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 21, 2020
    Assignee: Serene, LLC
    Inventors: Nigel R. Stevenson, Jaime Simon, Gilbert R. Gonzales
  • Patent number: 10527942
    Abstract: In a preferred aspect, organic coating compositions, particularly antireflective coating compositions for use with an overcoated photoresist, are provided that comprise 1) one or more glycidyl groups; and 2) one or more aromatic groups that each comprises two or more substituents that comprise hydroxy, thiol and/or amine moieties. Catechol-containing polymers and methods for producing same also are provided.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 7, 2020
    Assignee: Rohm and Haas Electronics Materials Korea Ltd.
    Inventors: Jae Hwan Sim, Jung Kyu Jo, EunHye Cho, Hye-Won Lee, Jin Hong Park, Eui-Hyun Ryu, Jae-Bong Lim
  • Patent number: 10517848
    Abstract: Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs. In some methods, the human subjects have been previously treated with one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs, and have developed at least partial tolerance to the one or more therapeutic agents.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: December 31, 2019
    Inventor: Louis M. Segreti
  • Patent number: 10472338
    Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 12, 2019
    Assignees: GE HEALTHCARE LIMITED, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
  • Patent number: 10465165
    Abstract: The present invention provides a multifunctional 2-D and 3-D matrix for propagation of stem cells. In particular, a chitosan-based biomaterial scaffold is engineered to promote CNS regeneration from primitive neural precursors by stabilizing a recombinant protein, fibroblast growth factor to preserve the cardinal properties of stem cells. The matrix, is further modified by the addition of either the extracellular matrix protein fibronectin or the small peptide RGD or IKVAV. A method to manufacture an injectable multifunctional microsphere scaffold is also disclosed that is suitable as a vehicle for cell transplantation to repair traumatic brain injuries.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: November 5, 2019
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NEW JERSEY INSTITUTE OF TECHNOLOGY
    Inventors: Cheul Cho, Steven Levison, Nolan Skop, Frances Calderon, Chirag Gandhi
  • Patent number: 10441669
    Abstract: Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: October 15, 2019
    Assignee: ILLINOIS INSTITUTE OF TECHNOLOGY
    Inventor: Hyun-Soon Chong
  • Patent number: 10434196
    Abstract: Disclosed herein are a multivalent saccharide complex, a radioactive multivalent saccharide complex contrast agent and use thereof. The multivalent saccharide complex has a chelator, a linker, and glucose, and is configured to diagnose and evaluate the therapeutic effect of cancers.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 8, 2019
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Hung-Man Yu, Wuu-Jyh Lin, Mei-Hui Wang, Chun-Hao Tseng
  • Patent number: 10406246
    Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: September 10, 2019
    Assignee: Deutsches Kresbsforschungszentrum
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
  • Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 10377778
    Abstract: The present invention relates complexes comprising a PSMA targeting compound linked to a radionuclide, such as 212Pb or 227Th. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 13, 2019
    Assignee: Sciencons AS
    Inventor: Roy Hartvig Larsen
  • Patent number: 10303846
    Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: May 28, 2019
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Eran Eden, Kfir Oved, Roy Navon, Assaf Cohen-Dotan, Olga Boico
  • Patent number: 10278657
    Abstract: A method for performing an imaging scan of a subject includes positioning a narrow field-of-view camera at a first imaging position to acquire a first set of imaging information of a first object of interest, positioning the narrow field-of-view camera at a second imaging position to acquire a second set of imaging information of a second object of interest, determining emission counts for the first and second sets of imaging information, and utilizing the determined emission counts to generate a value that indicates a probability of a successful medical procedure being performed on the subject.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: May 7, 2019
    Assignee: General Electric Company
    Inventors: Aharon Peretz, Yaron Hefetz, Lana Volokh
  • Patent number: 10233277
    Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 19, 2019
    Assignee: The Governing Council of the University of Toronto
    Inventors: Xiao Yu Wu, Alireza Shalviri, Ping Cai
  • Patent number: 10150804
    Abstract: Somatostatin derivative compounds of general formula (I) that may be readily labelled with the isotope fluorine-18 and that have affinity and selectivity for cellular somatostatin receptors are provided. The labelled compounds are useful clinically as radioactive tracers in various in vivo imaging applications (for example, using positron emission tomography (PET) and related techniques) to detect somatostatin-expressing cells and tissues, including tumors, or as therapeutic agents.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: December 11, 2018
    Assignees: BRITISH COLUMBIA CANCER AGENCY BRANCH, THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUSTRY LIAISON OFFICE
    Inventors: Francois Benard, Kuo-Shyan Lin, David Perrin, Zhibo Liu, Maral Pourghiasian
  • Patent number: 10071943
    Abstract: Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 11, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Peter J. H. Scott, Melanie S. Sanford, Naoko Ichiishi, Allen F. Brooks, Melissa Rodnick, Joseph J. Topczewski